Oncotarget

Research Papers:

p63 transcriptionally regulates the expression of matrix metallopeptidase 13

Ivana Celardo, Alexey Antonov, Ivano Amelio, Margherita Annicchiarico-Petruzzelli, Gerry Melino _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2014; 5:1279-1289. https://doi.org/10.18632/oncotarget.1778

Metrics: PDF 1142 views  |   HTML 1226 views  |   ?  


Abstract

Ivana Celardo1, Alexey Antonov1,2, Ivano Amelio1, Margherita Annicchiarico-Petruzzelli3 and Gerry Melino

1 Medical Research Council, Toxicology Unit, Leicester University, Leicester LE1 9HN, UK.

2 Saint-Petersburg State Institute of Technology, Saint- Petersburg, Russia.

3 Biochemistry Laboratory IDI-IRCC; Department of Experimental Medicine and Surgery; University of Rome “Tor Vergata”; Rome, Italy.

Correspondence:

Gerry Melino, email:

Keywords: p63, MMP13, Collagenase, skin, metastasis

Received: January 30, 2014 Accepted: Febrauary 12, 2014 Published: Febrauary 14, 2014

Abstract

p63 is a transcriptional factor belonging to p53 family of genes. Beside the role in cancer, partially shared with p53 and the other member p73, p63 also plays exclusive roles in development and homeostasis of ectodermal/epidermal-related organs. Here we show that p63 transcriptionally controls the expression of the matrix metallopeptidase 13 (MMP13). p63 binds a p53-like responsive element in the human promoter of MMP13, thus promoting the activation of its transcription. The catalytic activity of MMP13 is required in high invasion capacity of metastatic cancer cells, however, although p63 and MMP13 expression correlates in cancer patients, their co-expression does not predict cancer patient survival. Our results demonstrate that p63 directly controls MMP13 expression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1778